TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Lubiprostone Effect on Gastrointestinal Tract Transit Times Measured by Smartpill in Patients With Chronic Constipation

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2/PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* 18-65 years old~* At least a 6 months history of constipation. Constipation defined as follows:~  * Less than three complete spontaneous bowel movements per week and one or more of the following:~    1. At least 25% of stools are very hard and/or hard stools~   2. Sensation of incomplete evacuation following at least 25% of bowel movements.~   3. Straining on at least 25% of defecations. The above criteria are only applicable to spontaneous bowel movements. Patients who have no spontaneous bowel movements (bowel movements are preceded by laxative intake) are considered constipated and are eligible for this study.~* For patients ≥ 50 years of age, normal colonic anatomy as documented by colonoscopy, double-contrast barium enema, or flexible sigmoidoscopy performed within the previous 5 years.~Exclusion Criteria:~* Pregnancy or lactation.~* Subjects unwilling to practice adequate contraception throughout the period of screening through 14 days after the study termination.~* Use of laxatives 3 days immediately prior to randomization (except fiber or bulking agents).~* Use of any of the following drugs within 3 days prior to randomization:~  * Prokinetic agents (tegaserod, domperidone, cisapride, metoclopramide, erythromycin).~ * Medication containing opiates.~ * Anti-spasmodic (e.g., atropine, hyoscyamine, scopolamine, glycopyrrolate).~* Use of illegal drugs~* Regular consumption of 2 drinks of alcohol per day.~* Chronic nonsteroidal antiinflammatory drugs (NSAIDs) use~* Chronic use of H2 receptor antagonist or proton pump inhibitors (PPIs) within 14 days prior to screening.~* History of gastric or duodenal ulcer, inflammatory bowel disease(IBD), or chronic non-ulcer dyspepsia.~* Diabetes Mellitus (DM) type 1, Parkinson's disease.~* Existence of any medical condition that requires chronic therapy.~* Positive H. pylori serology~* Chronic active diverticulosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Lubiprostone (Type: EXPERIMENTAL): Lubiprostone 24 mcg by mouth twice a day (BID) for 2 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety of Saxagliptin VS. Glimepiride in Chinese T2DM Patients Controlled Inadequately With Metformin

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* For inclusion in the study subjects should fulfill the following criteria:~* Provision of informed consent prior to any study specific procedures~* Type2 diabetic patients had been on stable, maximum tolerated doses of metformin (≧1500mg/d, ≧8 weeks)~* Male or female age ≧ 25 years and ≦75 years old~* HbA1c ≧7.0 and ≦9.5%~* BMI ≧ 20 and ≦ 30 kg/m2~Exclusion Criteria:~* Subjects should not enter the study if any of the following exclusion criteria are fulfilled:~* Known or suspected allergy to trial products or related products.~* Impaired renal function defined as serum-creatinine ≥ 1.5 mg/dL (≥ 132.6 μmol/l).~* Acute or chronic disease which may cause tissue hypoxia such as cardiac or respiratory failure, shock.~* Hepatic insufficiency, acute alcohol intoxication, alcoholism.~* Subjects has a clinically significant, active (or over the past 12 months) cardiovascular history (including a history of myocardial infarction (MI), arrhythmias or conduction delays on ECG, unstable angina, or decompensated heart failure (New York Heart Association-class Ⅲ and Ⅳ).~* Proliferative retinopathy or muscular oedema requiring acute treatment.~* Lactation.~* Pregnant or positive pregnancy test at screening, nursing mother, or unwillingness to use adequate contraception (adequate contraceptive measures are sterilization, intrauterine device, oral contraceptives or barrier methods).~* Treatment with systemic corticosteroids within the past two months prior to screening.~* Tested positive for glutamic acid decarboxylase antibody.~* Receipt of any investigational drug within 1 month prior to this trial.

- Gender: ALL
- Minimum Age: 25 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Saxagliptin (Type: ACTIVE_COMPARATOR): The treatment of saxagliptin will be initiated and maintained at 5mg every morning until the completion of the test.Meanwhile,subjects will be instructed to take stable doses of metformin (1500mg/d) through the whole trial.
- Glimepiride (Type: ACTIVE_COMPARATOR): Glimepiride will be initially treated with 1 mg every morning to a dose of 6 mg/day.a.m. Every 4-week the subjects will be evaluated whether reach the target fasting plasma glucose (assayed by finger-stick ≦6.1 mmol/l ). If the fasting blood glucose not achieved the target at the maximum dose, maintain the maximum dose(6mg/d) until the completion of the test.Meanwhile,subjects will be instructed to take stable doses of metformin (1500mg/d) through the whole trial.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ambulatory Oxygen in Fibrotic Lung Disease (FLD) (AmbOx)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* IPF or another fibrotic ILD (including fibrotic NSIP, fibrotic organising pneumoni, and fibrotic hypersensitivity pneumonitis)~* patients aged 18 - 99 yrs~* Desaturation ≤ 88% on a 6MWT on room air~* Stable respiratory symptoms in the 4 weeks preceding the trial including the run in period~Exclusion Criteria:~* Patients meeting criteria for long term oxygen therapy, including hypercapnic patients~* Patients expected to change treatment during the course of the study~* Significant locomotor or communication difficulties and/or severe co-morbidities~* Patients with sarcoidosis or connective tissue disease affecting the musculoskeletal system~* Current smokers~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ambulatory oxygen cylinders (Type: ACTIVE_COMPARATOR): Subjects randomised to have the intervention of portable oxygen for the first two weeks. Only patients with stable symptoms at the end of the 'run in' period and reproducible 6-minute walk distance on the 6MWT during the baseline visit, as a marker of clinical stability of the disease will be randomized. They will be a portable oxygen cylinder during 2 weeks when they realize activities.
- no oxygen cylinders (Type: NO_INTERVENTION): Subjects randomised to be on air for the first two weeks of the treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: HuMax-CD20 in Active Rheumatoid Arthritis, Phase I/II

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age ≥ 18 years~* Active rheumatoid arthritis according to the American College of Rheumatology of at least six months duration with six or more swollen and six or more tender joints (of 28 joints) and Erythrocyte Sedimentation Rate (ESR) ≥ 22 mm/h and/or C-Reactive Protein (CRP) ≥ 10 mg/L (1 mg/dL).~* Treatment failure to one or more DMARDs.~* Treatment with methotrexate (7.5-25 mg/wk) for at least 12 weeks and at a stable dose for at least 4 weeks prior to planned start of trial treatment.~Exclusion Criteria:~* Use of DMARDs other than methotrexate.~* Current or previous (within four weeks of screening) participation in any other clinical trial.~* Previous exposure to other biological products within 4 weeks prior to planned start of trial treatment, and/or exposure to anti-CD20 antibodies within two years before screening for this trial.~* Any use of cyclophosphamide, nitrogen mustard, chlorambucil or other alkylating agents within five years before screening for this trial.~* Active autoimmune disease (other than RA and RA-associated secondary diseases) requiring immunosuppressive therapy.~* Past or current malignancy, except for resected cervical carcinoma Stage 1B or less, non-invasive basal cell and squamous cell skin carcinoma, malignant melanoma with a complete response of a duration of \> 10 years, or other cancer diagnoses with a complete response of a duration of \> 5 years.~* Chronic or current infectious disease including known or suspected positive serology for HIV, hepatitis B, or hepatitis C.~* Clinically significant cardiac disease, or history of significant cerebrovascular disease.~* Significant concurrent, uncontrolled medical condition including, but not limited to: renal, hepatic, hematological, gastrointestinal, endocrine, pulmonary, neurological, cerebral, or psychiatric disease.~* Breast feeding women, women with a positive pregnancy test at screening, or women of childbearing potential not willing to use adequate contraception during the trial.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Dose ranging (Type: PLACEBO_COMPARATOR): A double-blind, placebo controlled, dose escalation part randomized within each of 3 sequential cohorts (Part A),
- Parallel Arm RCT (Type: PLACEBO_COMPARATOR): a parallel group part with randomization into one of 4 treatment arms (Part B).

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Brain Markers of Treatment Response in Post-Traumatic Stress Disorder (PTSD)

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: BASIC_SCIENCE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Veterans with clinical diagnosis of post-traumatic stress disorder from combat related to deployment to Afghanistan/Iraq (Operation Enduring Freedom/Operation Iraqi Freedom)~Exclusion Criteria:~* Intolerance or sensitivity to paroxetine~* Major medical or neurologic illness~* Current psychotropic medication or active psychotherapy treatment~* Other major psychiatric illness

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 55 Years
- Healthy Volunteers: t

Study Arms:
- Arm 1 (Type: OTHER): Intervention-Paroxetine
- Arm 2 (Type: NO_INTERVENTION): No Intervention

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Behavioral Economics and Adherence in Teens (BEAT!)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ages 13-17~* Confirmed diagnosis of epilepsy~* Antiepileptic drug monotherapy~* Ability to read and speak English~Exclusion Criteria:~* No significant developmental delay (e.g., autism, moderate/severe developmental or intellectual disability) or comorbid medical diagnoses (e.g., diabetes)

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Control Group (Type: ACTIVE_COMPARATOR): Automated reminders and individualized adherence feedback reports
- Treatment Group (Type: EXPERIMENTAL): Automated reminders and individualized adherence feedback reports with social norms comparisons

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Tolerability of Ertapenem Sodium in the Treatment of Complicated Urinary Tract Infections (0826-055)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Adult patients with a suspected or documented complicated urinary tract infection~* Female patients must test negative for pregnancy and agree to use adequate birth control measures~* Nursing women must agree to defer breastfeeding until 5 days after completion of all study antibiotic therapy~Exclusion Criteria:~* Patients with complete obstruction of any portion of the urinary tract~* Patients with rapidly progressive or terminal illness~* Renal transplant patients

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- ertapenem sodium (MK0826) (Type: EXPERIMENTAL): ertapenem sodium
- ceftriaxone sodium (Type: ACTIVE_COMPARATOR): ceftriaxone sodium

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Treatment of OSA Associated Hypertension With Alpha 2 Agonist or Diuretic

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: CROSSOVER
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients ranging from 20 - 80 years~2. Body mass index (BMI) of 20-38 to include the typical obese OSA patients and avoid the practical difficulties in blood drawing from the massively obese~3. Hypertension with blood pressures \> 140/90 but less than 180/105 mmHg.~4. Apnea-hypopnea index above 10~Exclusion Criteria:~1. Receiving medications other than anti-hypertensives known to influence the sympathetic nervous system, sleep medicines (including heavy alcohol use) or drugs with adverse interactions with study medication.~2. Women who have premenstrual syndrome, or those who are pregnant or capable of pregnancy and unwilling to use effective non-hormonal contraception~3. Shift workers or have symptoms of narcolepsy, restless legs syndrome or insomnia, in order to minimize confounding effects of other sleep disorders~4. Have apneas which are primarily central~5. Have sleep fragmentation caused by syndromes such as chronic pain or movement disorders~6. Have diseases such as asthma or chronic obstructive pulmonary disease that compromises respiration.~7. Have known coronary or cerebral vascular disease, history of arrhythmias, cardiomyopathy, history of psychosis, current alcohol or drug abuse.~8. Have any contraindications to any study materials, such as heart block.~9. Have secondary hypertension~10. Have creatinine levels above 2.5 mg %, more than 1+ proteinuria by dipstick, hematuria or electrolyte disorders.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Placebo, Guanfacine, Hydrochlorothyazide (Type: EXPERIMENTAL): Sequence: Placebo, Then Guanfacine1 mg for 2 weeks followed by guanfacine 2 mg for 4 weeks, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks.
- Placebo, Hydrochlorothyazide, Guanfacine (Type: EXPERIMENTAL): Sequence: Placebo, Then Hydrochlorothiazide 12.5 mg for 2 weeks followed by hydrochlorothiazide 25 mg for 4 weeks, Then Guanfacine1 mg for 2 weeks followed by guanfacine 2 mg for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Comparing Cefepime Versus Cefazolin Plus Ceftazidime for CAPD-associated Peritonitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Age more than 18 years~* CAPD initiation more than 4 weeks~Exclusion Criteria:~* Exit site or tunnel infection~* Sepsis~* Previous CAPD-associated peritonitis treatment within 4 weeks~* Drug allergy to cephalosporin~* Tenckhoff catheter malfunction~* Hospitalization more than 48 hours~* Fungal or Mycobacterium infection~* Suspected secondary peritonitis~* Concomitant antibiotics.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (Type: EXPERIMENTAL): Cefepime intraperitoneal continuous dosing
- Control (Type: ACTIVE_COMPARATOR): Cefazolin plus Ceftazidime intraperitoneal continuous dosing

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Liraglutide in Combination With an OAD in Subjects With Type 2 Diabetes Insufficiently Controlled on OAD Alone

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Informed consent obtained before any trial-related activities (trial-related activities are any procedures that would not have been performed during normal management of the subject.)~* Japanese subjects with type 2 diabetes on monotherapy with an OAD (either glinide, metformin, a-glucosidase inhibitor or thiazolidinedione) within approved Japanese labelling in addition to diet and exercise therapy. Total daily dose and type of drug should have remained unchanged for at least 8 weeks prior to Visit 1~* Type 2 diabetes mellitus (clinically diagnosed) for at least 6 months~* HbA1c between 7.0-10.0% (both inclusive)~* Body Mass Index (BMI) below 40.0 kg/m\^2~* Outpatients who have no plans for an educational hospitalisation for the purpose of glycaemic control. However, hospitalisation for training of self-injection from Visit 2 that is for no longer than one week is allowed~* Subjects able and willing to perform self-monitoring of plasma glucose (SMPG)~Exclusion Criteria:~* Subjects with known or previous malignant tumor and are strongly suspected of recurrence (except basal cell skin cancer or squamous cell skin cancer)~* Calcitonin above or equal to 160 pg/mL~* Personal history of non-familial medullary thyroid carcinoma~* Family or personal history of multiple endocrine neoplasia type 2 (MEN-2) or familial medullary thyroid carcinoma (FMTC)~* History of chronic pancreatitis or idiopathic acute pancreatitis~* Recurrent severe hypoglycaemia (more than 1 severe hypoglycaemic event during the last 12 months) or hypoglycaemic unawareness as judged by the investigator or hospitalisation for diabetic ketoacidosis during the previous 6 months~* Treatment with GLP-1 receptor agonist or dipeptidyl peptidase 4 (DPP-4) inhibitor within 12 weeks prior to Visit 1~* Having contraindications to liraglutide and any of the OADs (according to Japanese labelling)

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Liraglutide + an OAD therapy (Type: EXPERIMENTAL): None
- Two OADs combination therapy (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Ultrasound-guided Transmuscular Quadratus Lumborum Block for Elective Laparoscopic Hand-assisted Nephrectomy and Robot Assisted Partiel Nephrectomy

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* over 18 years~* Kidney cancer~* Have received thorough information, orally and in written~* Signed the Informed Consent form on participation in the trial~Exclusion Criteria:~* Inability to cooperate~* Inability to speak and understand Danish both orally and written~* Allergy to local anaesthetics or opioids~* Daily intake of opioids~* Local infection at the site of injection or systemic infection~* Difficulty visualisation of muscular and fascial structures in ultrasound visualisation necessary to the block administration~* Known abuse of alcohol or medicine~* Pregnancy

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- TQL Ropivacaine(active) (Type: ACTIVE_COMPARATOR): Bilateral Single shot of ropivacaine 0.325% 30 mL. In total 60 mL of 0.325% ropivacaine
- TQL saline (placebo) (Type: PLACEBO_COMPARATOR): Bilateral single shot of saline 0.9% 30 mL. in Total 60 mL of saline 0.9%

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: RESPOND Post Market Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Subjects will be evaluated for eligibility by the clinical center's heart team per the local standard of practice in accordance with the Directions for Use.

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Lotus Valve (Type: None): All subjects who are candidates for Transcatheter Aortic Valve Implantation (TAVI), signed the Informed Consent Form (ICF) and are selected to receive a Lotus Valve.
- Lotus with Depth Guard (Type: None): All subjects who are candidates for Transcatheter Aortic Valve Implantation (TAVI), signed the Informed Consent Form (ICF) and are selected to receive a Lotus with Depth Guard.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete